Cargando…
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380484/ https://www.ncbi.nlm.nih.gov/pubmed/37511588 http://dx.doi.org/10.3390/ijms241411829 |
_version_ | 1785080206610923520 |
---|---|
author | Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gavriatopoulou, Maria |
author_facet | Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gavriatopoulou, Maria |
author_sort | Ntanasis-Stathopoulos, Ioannis |
collection | PubMed |
description | B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit. |
format | Online Article Text |
id | pubmed-10380484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103804842023-07-29 Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gavriatopoulou, Maria Int J Mol Sci Article B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit. MDPI 2023-07-23 /pmc/articles/PMC10380484/ /pubmed/37511588 http://dx.doi.org/10.3390/ijms241411829 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gavriatopoulou, Maria Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title_full | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title_fullStr | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title_full_unstemmed | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title_short | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma |
title_sort | real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380484/ https://www.ncbi.nlm.nih.gov/pubmed/37511588 http://dx.doi.org/10.3390/ijms241411829 |
work_keys_str_mv | AT ntanasisstathopoulosioannis realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT malandrakispanagiotis realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT fotioudespina realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT migkoumagdalini realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT theodorakakoufoteini realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT roussoumaria realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT eleutherakispapaiakovouevangelos realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT spiliopoulouvassiliki realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT kastritisefstathios realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT terposevangelos realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT dimopoulosmeletiosathanasios realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma AT gavriatopouloumaria realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma |